Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?

Exclusion Criteria

• •Patients with a medical condition that makes him/her a poor risk for upper endoscopy, conscious sedation, esophageal biopsy or ability to comply with study directives
• •Current use of blood thinners such as coumadin, warfarin, heparin and/or low molecular weight heparin, and rivaroxaban (requires discontinuation of medication 5 days prior to and 6 days after EGD)
• •Patients with known bleeding disorders
• •Patients who are status post partial or complete esophageal resection
• •Patients with a history of esophageal or gastric surgery, includes fundoplication, gastric bypass, etc.
• •Patients with a history of esophageal varices, esophageal cancer, achalasia, Barrett's esophagus, or eosinophilic esophagitis,
• •Current diagnosis of invasive esophageal cancer
• •Current use of calcium channel blockers, estradiol, immune suppressive drugs, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, and/or taxol/paclitaxel
• •Pregnant women
• •Patients with a history of being intolerant of Quercetin
• •Patients with continued moderate or severe heartburn despite use of twice daily PPIs (i.e. refractory to twice daily dosing of PPIs)
• •Patients with current active erosive esophagitis (assessed during baseline EGD).
• •Patients with a history of erosive esophagitis requiring PPI to treat. However, if patients have a history of erosive esophagitis and have discontinued PPI therapy at least 3 months prior to the baseline EGD, and there is no erosive disease seen during the baseline EGD, then these patients are eligible.
• •Patients with significant erosive gastropathy on baseline EGD requiring PPI to treat clinically.